NICE To Adjust Drug Appraisal Standards So Terminally Ill Patients Can Access More Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed cost-effectiveness criteria allow medicines in U.K. to be judged on ability to substantially extend life.
You may also be interested in...
Drug Price Versus Value: British Pharma Plans Public Debate In November
Having called for a public debate on how the United Kingdom values and provides access to new medicines, the Association of the British Pharmaceutical Industry is organizing to make it happen
U.K. Drug Spending Plan Balances 5% Cut With Increased Access
The U.K. National Health Service could save approximately £310 million in branded drug costs in 2009 under a preliminary agreement between the government and the pharmaceutical industry
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.